MAP1LC3C and central nervous system cancer: MAP1LC3C is a marker that indicates poor prognosis in patients with colon cancer, low-grade glioma and lung adenocarcinoma (Xu et al., 2020; Guo et al., 2021; Wang et al., 2021).